TY  - JOUR
ID  - eprints522
A1  - Shukuru, W.
A1  - Kagira, J.
A1  - Maina, N.
SP  - 190
Y1  - 2020/06/25/
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087916058&doi=10.36380%2fscil.2020.wvj25&partnerID=40&md5=d6febc0b1ee489fbbae35092104bf185
TI  - Toxicity, anthelmintic efficacy and proteolytic activity of chitosan-encapsulated bromelain within the gastrointestinal tract of small east african goats
KW  - Bromelain
KW  -  Chitosan
KW  -  Efficacy
KW  -  Goats
KW  -  Nanoencapsulation
KW  -  Proteolytic activity.
PB  - Scienceline Publication, Ltd
IS  - 2
N2  - The development of resistance to anthelmintic drugs has prompted researches into alternative methods for controlling intestinal nematodes in ruminants. This study aimed to evaluate the anthelmintic efficacy, proteolytic activity, and toxicity of bromelain encapsulated in chitosan within the gastrointestinal tract (GIT) of Small East African goats in Kenya. Twelve healthy indigenous male goats were divided into four groups contained three goats in each groups. Treatment groups included: G1, chitosan-encapsulated bromelain (90 mg/kg); G2, chitosan-encapsulated bromelain (270 mg/kg); G3, positive control (albendazole 7.5 mg/kg); and G4, negative control. The animals were orally treated with the drugs in a single dose. The hematological and serum biochemical parameters were determined using standard methods. The strongyle fecal egg count was evaluated weekly using a modified McMaster technique. To determine the proteolytic activity of nanoencapsulated bromelain within the GIT, another set of twelve goats was used and administered 270 mg/kg of encapsulated bromelain. Every four hours, three goats were sacrificed and the proteolytic activity of the drug was determined in the different organs of the GIT. Significant differences were observed between the mean PCV of goats treated with 270 mg/kg encapsulated bromelain and non-treated goats on days 21 and 28 post-treatment. The mean aspartate aminotransferase, urea, and creatinine levels of treated and control goats did not significantly differ during the experiment period. Also, no significant difference was observed between the mean alanine aminotransferase level of treated and untreated goats 28 days post-treatment. The administration of encapsulated bromelain was not associated with any clinical sign and mortality. The reduction in fecal egg count in G1 and G2 at 28 days post-treatment was 9.5% and 22.6%, respectively. The encapsulated bromelain remained proteolytically active along the goat GIT but its protease activity varied according to the type of GIT organ and time elapsed since administration. In conclusion, chitosan-encapsulated bromelain is safe, but have low efficacy against GIT strongyle nematodes when given as a single dose. Future studies should evaluate higher and repeated doses of encapsulated bromelain for controlling GIT nematodes.
JF  - World's Veterinary Journal
EP  - 198
VL  - 10
AV  - public
SN  - 23224568 (ISSN)
ER  -